Protecting America’s Medical Supply Chains Act of 2026

Ensuring availability of medical materials: The bill updates the Defense Production Act to ensure that medical materials essential to national defense, including drugs, devices, and biological products used to diagnose, cure, mitigate, treat, or prevent disease, are available (Section 2(a) and 2(b)).

Diversifying supply chains: The President is tasked with creating a strategy to diversify supply chains as required for national defense (Section 2(c)(a)(3)).

Reducing foreign control of essential components: The bill mandates a timeline to ensure essential components of the medical supply chain are not under the exclusive control of a foreign government that could threaten national defense (Section 2(c)(a)(4)(B)).

Increasing supply chain security through investment: The President may make payments to eligible domestic entities to increase the security of supply chains and supply chain activities, provided the payment is critical to meet national defense requirements (Section 3(a)).

Potential impact on production and costs: The required strategy must include a discussion of any significant effects the plan may have on the production, cost, or distribution of biological products, devices, or drugs (Section 2(c)(a)(4)(A)).

Risks to competitiveness and innovation: The President must consider and mitigate risks that the implementation of these measures might have on United States competitiveness, scientific leadership, and innovative capacity (Section 2(a) and 2(c)(a)(4)(C)).